Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Open in Screener

FATE

Fate Therapeutics Inc

Nov 25 • 04:00PM ET

1.06

-0.02 -1.85 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD CRSP BLUE SRPT EDIT NTLA CLLS SGMO TVRD VTVT

| Held by: VTI IWM VXF IWN IBB VTWO SCHA DFAT VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-1.32	Insider Own	4.91%	Shs Outstand	115.34M	Perf Week	3.92%
Market Cap	122.27M	Forward P/E	-	EPS next Y	-1.16	Insider Trans	-0.41%	Shs Float	109.69M	Perf Month	-31.61%
Enterprise Value	-13.90M	PEG	-	EPS next Q	-0.27	Inst Own	71.34%	Short Float	6.23%	Perf Quarter	-5.36%
Income	-156.09M	P/S	17.13	EPS this Y	29.83%	Inst Trans	0.84%	Short Ratio	3.19	Perf Half Y	-16.54%
Sales	7.14M	P/B	0.52	EPS next Y	-0.58%	ROA	-37.23%	Short Interest	6.83M	Perf YTD	-35.76%
Book/sh	2.03	P/C	0.57	EPS next 5Y	11.86%	ROE	-52.35%	52W High	3.43 -69.10%	Perf Year	-48.79%
Cash/sh	1.87	P/FCF	-	EPS past 3/5Y	9.89% -2.63%	ROIC	-50.59%	52W Low	0.66 60.35%	Perf 3Y	-94.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-37.51% 5.00%	Gross Margin	-105.28%	Volatility	8.52% 9.71%	Perf 5Y	-97.87%
Dividend TTM	-	EV/Sales	-1.95	EPS Y/Y TTM	20.26%	Oper. Margin	-2241.75%	ATR (14)	0.11	Perf 10Y	-75.69%
Dividend Ex-Date	-	Quick Ratio	7.87	Sales Y/Y TTM	-46.92%	Profit Margin	-2187.11%	RSI (14)	43.48	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.87	EPS Q/Q	33.05%	SMA20	-3.85%	Beta	2.36	Target Price	4.94
Payout	-	Debt/Eq	0.34	Sales Q/Q	-43.36%	SMA50	-13.97%	Rel Volume	0.44	Prev Close	1.08
Employees	181	LT Debt/Eq	0.32	Earnings	Nov 13 BMO	SMA200	-7.60%	Avg Volume	2.14M	Price	1.06
IPO	Oct 01, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.57% 20.89%	Trades		Volume	938,167	Change	-1.85%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Oct-27-25	Upgrade	Wedbush	Neutral → Outperform	$7
Nov-18-24	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $6
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$6
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral	$115 → $7
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral	$42 → $7
Jan-06-23	Downgrade	Truist	Buy → Hold	$46 → $7
Jan-06-23	Downgrade	Stifel	Buy → Hold	$107 → $5.30
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral	$71 → $12
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$72 → $4
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$20 → $7
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell	$10
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight	$98 → $45
Oct-10-22	Initiated	Canaccord Genuity	Buy	$42
Aug-18-22	Resumed	Wells Fargo	Overweight	$90
Jul-28-22	Initiated	Needham	Hold

Show Previous Ratings

Today 08:00AM	Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 09:40AM	Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
08:30AM	Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Nov-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.56% -8.40%
10:00AM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
11:35AM	Loading…
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
08:15AM	Incyte (INCY) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-26-25 11:30AM	Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy (GlobeNewswire)
Oct-14-25 08:00AM	Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer (GlobeNewswire) +7.91%
Oct-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-25-25 08:00AM	Fate Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -5.22%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire) -5.31%
Aug-12-25 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +20.69%
04:30PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-11-25 06:55PM	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Aug-07-25 06:25PM	Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates (Zacks) -5.76% -5.99%
Aug-06-25 07:45AM	Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-05-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-25 04:57PM	Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data (Insider Monkey)
07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire)
Jul-03-25 01:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 11:30AM	Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? (Zacks) -9.68%
Jun-11-25 09:00AM	Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress (GlobeNewswire) -7.19%
Jun-10-25 10:23AM	Top Cancer Stocks to Supercharge Your 2025 Portfolio (Zacks) +9.87%
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire) -8.33% +7.44%
May-28-25 11:46PM	Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases (Insider Monkey)
05:54PM	Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress (GlobeNewswire)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
05:15PM	Loading…
May-13-25 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.54%
04:01PM	Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
May-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.65% -10.69%
Apr-29-25 09:25AM	Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting (GlobeNewswire) -6.40%
Apr-15-25 10:42AM	Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag (Zacks) +21.17%
Apr-14-25 08:00AM	Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) (GlobeNewswire) -12.80%
Apr-04-25 11:30AM	Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? (Zacks) +10.72%
Apr-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.69%
Mar-05-25 05:10PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +14.90%
04:12PM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Mar-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.77%
Feb-17-25 10:00AM	Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-14-25 04:01PM	Fate Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +11.81% +7.75%
Feb-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.40%
Jan-03-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-12-24 11:30AM	Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? (Zacks) -11.70%
Dec-09-24 04:01PM	Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus (GlobeNewswire) -16.18%
Dec-03-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.15%
Dec-02-24 09:55AM	Fate Therapeutics makes Bob Valamehr president and CEO (Pharmaceutical Technology) -6.62%
Nov-29-24 01:05PM	Fate Therapeutics Announces Leadership Transition (GlobeNewswire)
Nov-26-24 04:01PM	Fate Therapeutics to Present at Upcoming December Investor Conferences (GlobeNewswire) +10.74% +18.28%
Nov-18-24 08:05AM	Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence (GlobeNewswire) +12.38%
08:00AM	Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence (GlobeNewswire)
Nov-12-24 05:20PM	Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.03% -8.82%
04:18PM	Fate Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Nov-09-24 01:30PM	Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting (GlobeNewswire)
Nov-08-24 04:01PM	Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting (GlobeNewswire) -5.10% +5.79%
Nov-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.58%
Oct-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-24 04:01PM	Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference (GlobeNewswire) +7.49%
11:30AM	Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? (Zacks)
Aug-16-24 12:00PM	All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy (Zacks)
Aug-13-24 05:25PM	Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Aug-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.12% -9.50%
Jul-31-24 08:00AM	Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors (GlobeNewswire)
Jul-21-24 05:37AM	Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? (Motley Fool)
Jul-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 04:01PM	Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 10:48AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 02:50PM	Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ... (GuruFocus.com)
10:36AM	Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating (MT Newswires)
08:22AM	Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating (MT Newswires)
May-09-24 08:58PM	FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.41%
05:25PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Fate Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
08:30AM	Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program (GlobeNewswire)
May-06-24 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
May-03-24 04:30PM	Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting (GlobeNewswire)
Apr-22-24 04:30PM	Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting (GlobeNewswire) -5.02%
Apr-06-24 02:17AM	Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress (Zacks)
Apr-04-24 11:30PM	NOTICE TO LONG-TERM SHAREHOLDERS OF FATE THERAPEUTICS, INC. (FATE): GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON YOUR BEHALF (Newsfile)
Apr-03-24 08:00AM	Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-24 11:30AM	Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound? (Zacks) +7.00%
Mar-19-24 08:44AM	Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement (GlobeNewswire)
Mar-05-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.15%
Mar-01-24 08:09AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.17%
08:00AM	Fate Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-27-24 09:16AM	Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y (Zacks) +7.34%
08:07AM	Q4 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-24 05:10PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:35PM	Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
04:08PM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates (GlobeNewswire)

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TAHL CINDY	See Remarks	Aug 04 '25	Sale	1.06	9,037	9,573	397,670	Aug 05 04:03 PM
Valamehr Bahram	President and CEO	Aug 04 '25	Sale	1.06	14,466	15,396	334,898	Aug 05 04:02 PM
TAHL CINDY	Officer	Aug 04 '25	Proposed Sale	1.06	9,037	9,573		Aug 04 04:56 PM
Valamehr Bahram	Officer	Aug 04 '25	Proposed Sale	1.06	14,466	15,396		Aug 04 04:17 PM
Wolchko J Scott	Former Officer and Director	Mar 06 '25	Proposed Sale	0.93	113,178	104,881		Mar 06 01:52 PM
Bressi Jerome Charles	See Remarks	Jan 10 '25	Sale	1.55	5,980	9,269	270,203	Jan 13 04:06 PM
TAHL CINDY	See Remarks	Jan 10 '25	Sale	1.55	5,654	8,764	336,707	Jan 13 04:05 PM
Valamehr Bahram	President and CEO	Jan 10 '25	Sale	1.54	8,705	13,406	349,364	Jan 13 04:04 PM
Valamehr Bahram	Officer	Jan 10 '25	Proposed Sale	1.54	8,705	13,447		Jan 10 03:20 PM
Bressi Jerome Charles	Officer	Jan 10 '25	Proposed Sale	1.55	5,980	9,276		Jan 10 03:12 PM
TAHL CINDY	Officer	Jan 10 '25	Proposed Sale	1.55	5,654	8,782		Jan 10 03:12 PM
Redmile Group, LLC	Director	Dec 20 '24	Buy	1.68	397,964	668,580	12,884,277	Dec 26 09:00 PM
Redmile Group, LLC	Director	Dec 20 '24	Sale	1.68	341,633	573,943	12,486,313	Dec 26 09:00 PM
Redmile Group, LLC	Director, 10% Stockholder	Dec 20 '24	Proposed Sale	1.66	341,633	567,111		Dec 20 09:00 PM

Open in Screener

ADCT

Adc Therapeutics SA

Nov 25 • 04:00PM ET

4.39

+0.02 0.46 %

Healthcare • Biotechnology • Switzerland • NYSE

ADCT Adc Therapeutics SA daily Stock Chart

Peers: GILD PFE AMGN LLY REGN VRTX JAZZ MRNA BMY INCY

| Held by: IWM IBB IWO VTWO IWC GWX VTWG IWV RSSL URTY

Index	RUT	P/E	-	EPS (ttm)	-1.45	Insider Own	19.84%	Shs Outstand	112.63M	Perf Week	9.75%
Market Cap	543.82M	Forward P/E	-	EPS next Y	-1.11	Insider Trans	0.00%	Shs Float	99.31M	Perf Month	2.33%
Enterprise Value	766.52M	PEG	-	EPS next Q	-0.29	Inst Own	52.66%	Short Float	6.53%	Perf Quarter	36.34%
Income	-166.94M	P/S	7.23	EPS this Y	12.76%	Inst Trans	1.77%	Short Ratio	7.35	Perf Half Y	65.66%
Sales	75.21M	P/B	-	EPS next Y	21.46%	ROA	-52.26%	Short Interest	6.48M	Perf YTD	120.60%
Book/sh	-2.11	P/C	2.32	EPS next 5Y	21.36%	ROE	-	52W High	4.80 -8.54%	Perf Year	126.29%
Cash/sh	1.89	P/FCF	-	EPS past 3/5Y	18.47% 1.38%	ROIC	-76.47%	52W Low	1.05 318.10%	Perf 3Y	11.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	27.82% 97.79%	Gross Margin	89.33%	Volatility	6.69% 7.18%	Perf 5Y	-86.90%
Dividend TTM	-	EV/Sales	10.19	EPS Y/Y TTM	39.57%	Oper. Margin	-162.94%	ATR (14)	0.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.34	Sales Y/Y TTM	6.35%	Profit Margin	-221.97%	RSI (14)	59.94	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.63	EPS Q/Q	28.44%	SMA20	5.64%	Beta	1.88	Target Price	8.00
Payout	-	Debt/Eq	-	Sales Q/Q	-11.03%	SMA50	7.80%	Rel Volume	0.60	Prev Close	4.37
Employees	265	LT Debt/Eq	-	Earnings	Nov 10 BMO	SMA200	57.75%	Avg Volume	881.45K	Price	4.39
IPO	May 15, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.42% -2.18%	Trades		Volume	525,106	Change	0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-08-24	Initiated	Stephens	Overweight	$6
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy	$11
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform	$7 → $2
Dec-06-22	Initiated	CapitalOne	Overweight	$12
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral	$14 → $7
Sep-21-22	Initiated	JP Morgan	Overweight	$5
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $11
Nov-09-21	Initiated	Wolfe Research	Outperform	$44
Aug-17-21	Resumed	Jefferies	Buy	$40
Aug-09-21	Initiated	RBC Capital Mkts	Outperform	$33
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight	$13
Dec-03-20	Initiated	Stifel	Hold	$42
Oct-29-20	Initiated	H.C. Wainwright	Buy	$47
Jun-09-20	Initiated	Cowen	Outperform
Jun-09-20	Initiated	BofA/Merrill	Buy	$45

Show Previous Ratings

Nov-18-25 12:00PM	ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-10-25 04:01PM	ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue ... (GuruFocus.com) -5.70%
08:40AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
Nov-07-25 12:51PM	Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y (Zacks)
07:20AM	Loading…
07:20AM	ADC Therapeutics SA (ADCT) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-06-25 05:45PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-03-25 06:05PM	Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.28%
07:15AM	ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025 (PR Newswire)
Oct-27-25 07:15AM	ADC Therapeutics to Present at November Investor Conferences (PR Newswire)
Oct-26-25 06:16AM	ADC Therapeutics (ADCT) Secures PIPE Financing, Price Target Adjusted (Insider Monkey)
Oct-24-25 08:07AM	H.C. Wainwright Lowers ADC Therapeutics (ADCT) PT to $7 Following $60M Private Placement (Insider Monkey)
Oct-13-25 01:06PM	Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain (Zacks)
07:30AM	ADC Therapeutics Announces $60 Million Private Placement (PR Newswire)
Oct-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
12:56AM	Loading…
Sep-29-25 12:56AM	ADC Therapeutics S.A. (ADCT) Eyes Billion Dollar Opportunity with ZYNLATA Indication Expansion (Insider Monkey) +10.14%
Sep-18-25 10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +6.13%
Aug-27-25 07:15AM	ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025 (PR Newswire)
Aug-13-25 03:07AM	ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... (GuruFocus.com) +5.10%
Aug-12-25 03:00PM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.70%
07:30AM	ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
Aug-11-25 07:00PM	TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
09:34AM	ADC Therapeutics SA (ADCT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-07-25 06:10PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 04:05PM	ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 (PR Newswire)
Aug-04-25 09:40AM	Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? (Zacks)
Aug-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Jul-01-25 04:05PM	ADC Therapeutics Makes Grant to New Employee Under Inducement Plan (PR Newswire)
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
07:15AM	Loading…
Jun-16-25 07:15AM	ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML) (PR Newswire) -5.59%
Jun-12-25 06:45AM	ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 (PR Newswire)
06:30AM	ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress (PR Newswire)
Jun-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +13.59%
May-30-25 05:44AM	AbbVies ADC win shows how pharma can break through in solid tumors (Pharma Voice) +11.55%
May-15-25 07:49AM	ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data (Clinical Trials Arena) -6.63%
07:15AM	ADC Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-14-25 09:10AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +37.12%
08:00AM	ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
07:45AM	ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) (PR Newswire)
May-13-25 09:42AM	What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings (GuruFocus.com)
May-08-25 05:50PM	Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:15AM	ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 (PR Newswire)
May-01-25 05:25PM	Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-30-25 08:15AM	AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-29-25 10:01AM	Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-28-25 10:00AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +9.77%
07:00AM	ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 (PR Newswire)
Apr-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
07:15AM	ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-31-25 09:00PM	ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) -5.37%
Mar-27-25 11:17AM	ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:35AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update (PR Newswire)
Mar-25-25 05:30PM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 (PR Newswire)
Mar-24-25 11:08PM	ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 (SeekingAlpha)
Mar-20-25 07:15AM	ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025 (PR Newswire) -6.59%
Feb-03-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) -5.95%
Jan-30-25 07:15AM	ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference (PR Newswire)
Jan-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Dec-30-24 04:30PM	ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma (PR Newswire) -6.40%
Dec-11-24 07:30AM	ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (PR Newswire) -36.21%
Dec-09-24 07:30AM	ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma (PR Newswire)
Dec-06-24 07:30AM	ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial (PR Newswire) +63.02%
Dec-02-24 04:30PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) -10.78%
Nov-14-24 02:02AM	BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ... (GuruFocus.com) -6.03%
Nov-08-24 01:14PM	ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why (Benzinga)
Nov-07-24 08:50AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.44%
07:30AM	ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update (PR Newswire)
Nov-06-24 07:41AM	What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings (GuruFocus.com)
Nov-05-24 09:47AM	ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting (PR Newswire)
Nov-04-24 07:15AM	ADC Therapeutics to Present at November Investor Conferences (PR Newswire)
Nov-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
09:40AM	Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-31-24 07:15AM	ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (PR Newswire)
Oct-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire)
Sep-03-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) -5.86%
07:15AM	ADC Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-06-24 08:40AM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Aug-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) -7.83% -5.88%
Jul-30-24 07:15AM	ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024 (GlobeNewswire)
Jul-11-24 03:24PM	7 Growth Stocks to Buy for Under $5 for Massive Gains (InvestorPlace) +20.32%
Jul-08-24 02:00AM	Myricx Bio Announces 90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development (GlobeNewswire) -6.13%
Jul-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +16.46% -5.43%
Jun-27-24 07:15AM	ADC Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-13-24 02:31PM	Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget (InvestorPlace)
Jun-03-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +5.74%
May-30-24 07:15AM	ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-24 07:15AM	ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-09-24 07:01PM	Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT) (GuruFocus.com) -5.91%
07:15AM	ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-07-24 08:55AM	ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript (Insider Monkey) +8.54%
08:44AM	HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating (MT Newswires)
May-06-24 10:53AM	ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -9.18%
08:22AM	ADC Therapeutics Launches $105 Million Offering; Shares Up 2% Pre-Bell (MT Newswires)
07:30AM	ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
07:20AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:55AM	ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial (MT Newswires)
06:10AM	ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Redmile Group, LLC	10% Owner	Dec 11 '24	Buy	3.04	100,000	304,500	15,666,731	Dec 13 09:00 PM
Redmile Group, LLC	10% Owner	Dec 11 '24	Buy	3.04	100,000	304,500	13,145,712	Dec 13 09:00 PM
Redmile Group, LLC	10% Owner	Dec 04 '24	Sale	2.07	25,352	52,479	15,566,731	Dec 06 09:00 PM

Open in Screener

STTK

Shattuck Labs Inc

Nov 25 • 04:00PM ET

2.01

-0.05 -2.43 %

Healthcare • Biotechnology • USA • NASD

STTK Shattuck Labs Inc daily Stock Chart

Peers: KURA ADAP FATE DTIL AFMD ALXO HOOK ALDX IMTX

| Held by: VTI VXF AVSC

Index	-	P/E	-	EPS (ttm)	-1.02	Insider Own	21.55%	Shs Outstand	63.15M	Perf Week	0.00%
Market Cap	127.20M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	-	Shs Float	49.64M	Perf Month	-2.43%
Enterprise Value	43.70M	PEG	-	EPS next Q	-0.14	Inst Own	46.75%	Short Float	1.83%	Perf Quarter	101.00%
Income	-54.90M	P/S	127.20	EPS this Y	48.01%	Inst Trans	2.35%	Short Ratio	1.42	Perf Half Y	93.27%
Sales	1.00M	P/B	1.36	EPS next Y	31.52%	ROA	-51.77%	Short Interest	0.91M	Perf YTD	66.12%
Book/sh	1.48	P/C	1.48	EPS next 5Y	31.92%	ROE	-57.84%	52W High	2.70 -25.69%	Perf Year	99.01%
Cash/sh	1.36	P/FCF	-	EPS past 3/5Y	-11.56% -20.93%	ROIC	-57.79%	52W Low	0.69 190.40%	Perf 3Y	-1.47%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-42.45% -10.36%	Gross Margin	-272.20%	Volatility	9.63% 8.51%	Perf 5Y	-93.33%
Dividend TTM	-	EV/Sales	43.70	EPS Y/Y TTM	33.32%	Oper. Margin	-5770.30%	ATR (14)	0.18	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.00	Sales Y/Y TTM	-84.46%	Profit Margin	-5489.50%	RSI (14)	52.31	Recom	2.20
Dividend Gr. 3/5Y	- -	Current Ratio	17.00	EPS Q/Q	57.53%	SMA20	2.60%	Beta	1.69	Target Price	3.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-66.63%	SMA50	-2.78%	Rel Volume	0.09	Prev Close	2.06
Employees	44	LT Debt/Eq	0.02	Earnings	Nov 06 AMC	SMA200	53.62%	Avg Volume	640.49K	Price	2.01
IPO	Oct 09, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.79% -	Trades		Volume	56,056	Change	-2.43%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-08-25	Initiated	Wedbush	Outperform	$4
Mar-17-25	Initiated	Leerink Partners	Outperform	$4
Oct-02-24	Downgrade	Needham	Buy → Hold
Oct-02-24	Downgrade	Citigroup	Buy → Neutral	$8 → $2
Oct-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Aug-31-22	Initiated	BTIG Research	Buy	$12
Jun-01-22	Initiated	Citigroup	Buy	$13
May-02-22	Initiated	H.C. Wainwright	Buy	$28
Apr-14-21	Initiated	Berenberg	Buy	$47
Jan-11-21	Initiated	Evercore ISI	Outperform
Nov-03-20	Initiated	Needham	Buy	$34
Nov-03-20	Initiated	Cowen	Outperform
Nov-03-20	Initiated	Citigroup	Buy	$36

Show Previous Ratings

Nov-20-25 08:00AM	Shattuck Labs to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-06-25 04:30PM	Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-08-25 12:00PM	What Makes Shattuck Labs, Inc. (STTK) a Strong Momentum Stock: Buy Now? (Zacks)
Oct-02-25 07:51AM	Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel (GlobeNewswire)
Sep-19-25 09:55AM	Should You Buy Shattuck Labs, Inc. (STTK) After Golden Cross? (Zacks)
05:09PM	Loading…
Sep-08-25 05:09PM	Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +21.29% +6.91%
Aug-26-25 06:30AM	Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors (GlobeNewswire)
Aug-21-25 10:17AM	Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease (GlobeNewswire) -11.42%
Aug-14-25 06:30AM	Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +6.13%
Aug-05-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +33.30%
06:30AM	Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million (GlobeNewswire)
Jul-02-25 07:00AM	Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
May-01-25 04:20PM	Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +9.20% -7.81%
Apr-02-25 05:00PM	Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +16.28% -17.34%
Mar-27-25 07:00AM	Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
09:00AM	Loading…
Feb-20-25 09:00AM	Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 (GlobeNewswire)
Feb-13-25 04:30PM	Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 (GlobeNewswire) +5.04% +6.40%
Feb-04-25 07:00AM	Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress (GlobeNewswire)
Jan-06-25 04:59PM	Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.22%
Jan-03-25 07:15AM	Shattuck Labs highlights upcoming key milestones in 2025 (TipRanks) +10.74%
Jan-02-25 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025 (GlobeNewswire)
Nov-25-24 07:00AM	Shattuck Labs Announces Participation in Upcoming December Conferences (GlobeNewswire)
Nov-15-24 07:12AM	Shattuck Labs sees cash runway into 2027 (TipRanks) -9.85%
Nov-14-24 07:00AM	Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +12.30%
Oct-24-24 09:35AM	Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround (Zacks)
Oct-08-24 09:35AM	After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) (Zacks) +11.50%
Oct-02-24 11:32AM	Shattuck Labs stock craters following pipeline and job cuts (Pharmaceutical Technology) -34.90%
06:57AM	Shattuck Labs Refocuses Strategy Amidst Restructuring and Cuts (TipRanks)
Oct-01-24 12:26PM	Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline (Benzinga) -44.99%
06:30AM	Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway (GlobeNewswire)
06:20PM	Loading…
Aug-01-24 06:20PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.28%
04:05PM	Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-30-24 05:00PM	Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-01-24 06:00AM	Shattuck Labs Announces Addition to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-18-24 06:25PM	Yigal Nochomovitz Just Trimmed Price Target for Shattuck Labs, Inc. (NASDAQ:STTK) (Insider Monkey) -7.83% -9.26%
10:48AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
Jun-14-24 01:28PM	Shattuck (STTK) Announces Positive Interim Data on Cancer Drug (Zacks) -9.50%
06:00AM	Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Jun-10-24 07:30AM	Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire)
Jun-06-24 07:30AM	Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
May-21-24 09:35AM	After Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK) (Zacks)
May-14-24 04:15PM	Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress (GlobeNewswire) -18.07%
May-07-24 12:00PM	What Makes Shattuck Labs (STTK) a New Buy Stock (Zacks)
09:55AM	Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect? (Zacks)
May-04-24 05:31AM	Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-02-24 09:58PM	STTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:25AM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:05AM	Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-09-24 04:05PM	Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +8.44%
Apr-01-24 07:00AM	Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-04-24 07:00AM	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors (GlobeNewswire)
Feb-29-24 04:05PM	Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +10.54%
Feb-26-24 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-14-24 05:06AM	Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins (PR Newswire) +6.03%
Feb-13-24 06:00AM	Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases (GlobeNewswire) -5.37%
Jan-08-24 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024 (GlobeNewswire) +14.94%
Jan-04-24 04:05PM	Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +12.14%
Dec-21-23 08:00AM	Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants (GlobeNewswire)
Dec-13-23 10:45AM	Why Is Shattuck Labs (STTK) Stock Up 93% Today? (InvestorPlace) +130.33%
06:00AM	Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Dec-05-23 04:15PM	Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023 (GlobeNewswire) +22.56%
Nov-14-23 09:00AM	Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +10.05%
Nov-13-23 08:52AM	Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 11:54PM	Q3 2023 Shattuck Labs Inc Earnings Call (Thomson Reuters StreetEvents) -23.21%
08:29AM	Shattuck Labs Inc (STTK) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
06:00AM	Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-06-23 09:28AM	Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023 (GlobeNewswire) +14.05%
Nov-02-23 09:01AM	Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +7.69%
Aug-10-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.64%
04:00PM	Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-06-23 10:14AM	Companies Like Shattuck Labs (NASDAQ:STTK) Could Be Quite Risky (Simply Wall St.) -7.07%
May-25-23 05:15PM	Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) -5.46%
May-09-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.56%
04:00PM	Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-03-23 07:00AM	Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-23 11:50AM	Great week for Shattuck Labs, Inc. (NASDAQ:STTK) institutional investors after losing 37% over the previous year (Simply Wall St.)
Mar-16-23 08:31AM	Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +8.93%
Mar-01-23 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-27-23 10:46PM	Shattuck Labs, Inc. (NASDAQ:STTK) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-23-23 04:30PM	Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-16-23 07:00AM	Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023 (GlobeNewswire)
Feb-09-23 06:01AM	Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-27-23 08:34AM	We Think Shattuck Labs (NASDAQ:STTK) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jan-09-23 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023 (GlobeNewswire)
Dec-13-22 06:51AM	Multiple insiders bought Shattuck Labs, Inc. (NASDAQ:STTK) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Dec-01-22 09:55AM	Shattuck Labs, Inc. (STTK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-11-22 05:51AM	Shattuck Labs Third Quarter 2022 Earnings: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021) (Simply Wall St.)
Nov-08-22 04:30PM	Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -6.75% -5.88%
Nov-07-22 08:00AM	Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-04-22 11:55AM	Investors in Shattuck Labs (NASDAQ:STTK) have unfortunately lost 86% over the last year (Simply Wall St.)
Nov-03-22 08:30AM	Shattuck Labs Announces Participation in Upcoming November Conferences (GlobeNewswire)
Nov-01-22 04:30PM	Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire) -8.66%
Oct-12-22 10:04AM	Owning 38% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK), (Simply Wall St.) +10.51%
Oct-05-22 04:30PM	Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12 (GlobeNewswire) +10.00%
Sep-01-22 04:15PM	Shattuck Labs Announces Participation in Upcoming September Conferences (GlobeNewswire)
Aug-20-22 08:41AM	We Think Shattuck Labs (NASDAQ:STTK) Needs To Drive Business Growth Carefully (Simply Wall St.)
Aug-11-22 07:00AM	Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-06-22 07:20AM	Quite a few insiders invested in Shattuck Labs, Inc. (NASDAQ:STTK) last year which is positive news for shareholders (Simply Wall St.) +20.93%
May-28-22 08:05AM	Shareholders in Shattuck Labs (NASDAQ:STTK) are in the red if they invested a year ago (Simply Wall St.)

Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. It focuses on developing a potential first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORBIMED ADVISORS LLC	Director	Aug 25 '25	Buy	0.87	6,306,127	5,471,826	5,255,106	Sep 02 09:52 PM
Ashiya Mona	Director	Aug 25 '25	Buy	0.87	6,306,127	5,471,826	5,255,106	Sep 02 09:50 PM
Redmile Group, LLC	Director	Dec 04 '24	Buy	1.25	133,371	166,714	5,539,724	Dec 06 09:00 PM
Redmile Group, LLC	Director	Dec 04 '24	Sale	1.25	133,371	166,714	5,406,353	Dec 06 09:00 PM
Redmile Group, LLC	Director, 10% Stockholder	Dec 04 '24	Proposed Sale	1.13	133,371	150,709		Dec 04 09:00 PM

Open in Screener

ABSI

Absci Corp

Nov 25 • 04:00PM ET

3.07

+0.11 3.72 %

Healthcare • Biotechnology • USA • NASD

Peers: INCY VRTX REGN BMRN SRPT EXEL NBIX IONS ALNY CRSP

| Held by: ARKG VTI IWM VXF IBB VTWO IWO SCHA VFMO IWC

Index	RUT	P/E	-	EPS (ttm)	-0.90	Insider Own	9.75%	Shs Outstand	149.75M	Perf Week	8.10%
Market Cap	461.64M	Forward P/E	-	EPS next Y	-0.64	Insider Trans	1.07%	Shs Float	135.71M	Perf Month	-31.78%
Enterprise Value	299.04M	PEG	-	EPS next Q	-0.18	Inst Own	65.07%	Short Float	22.40%	Perf Quarter	20.39%
Income	-114.60M	P/S	164.29	EPS this Y	11.70%	Inst Trans	5.46%	Short Ratio	5.76	Perf Half Y	12.04%
Sales	2.81M	P/B	2.19	EPS next Y	22.89%	ROA	-47.73%	Short Interest	30.39M	Perf YTD	17.18%
Book/sh	1.40	P/C	2.73	EPS next 5Y	6.53%	ROE	-55.68%	52W High	6.33 -51.50%	Perf Year	20.39%
Cash/sh	1.12	P/FCF	-	EPS past 3/5Y	5.67% -29.30%	ROIC	-53.68%	52W Low	2.01 52.74%	Perf 3Y	35.84%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.76% 17.09%	Gross Margin	-331.55%	Volatility	8.14% 8.07%	Perf 5Y	-
Dividend TTM	-	EV/Sales	106.42	EPS Y/Y TTM	3.38%	Oper. Margin	-4229.13%	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.89	Sales Y/Y TTM	-33.09%	Profit Margin	-4071.19%	RSI (14)	42.99	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.89	EPS Q/Q	17.21%	SMA20	-8.96%	Beta	2.19	Target Price	7.97
Payout	-	Debt/Eq	0.03	Sales Q/Q	-77.78%	SMA50	-13.28%	Rel Volume	0.70	Prev Close	2.96
Employees	157	LT Debt/Eq	0.02	Earnings	Nov 12 AMC	SMA200	-2.25%	Avg Volume	5.28M	Price	3.07
IPO	Jul 22, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.44% -76.07%	Trades		Volume	3,667,747	Change	3.72%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-02-25	Initiated	JP Morgan	Overweight
Jul-03-25	Resumed	Morgan Stanley	Overweight	$7
Jan-22-25	Initiated	Needham	Buy	$9
Oct-02-24	Initiated	Guggenheim	Buy	$10
Jul-03-24	Initiated	Morgan Stanley	Overweight	$7
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$13
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$3
May-04-23	Initiated	H.C. Wainwright	Buy	$4
Aug-12-22	Downgrade	JP Morgan	Overweight → Underweight
Jul-18-22	Initiated	Truist	Buy	$8
Mar-02-22	Resumed	Cowen	Market Perform
Feb-01-22	Initiated	Berenberg	Buy	$28
Nov-10-21	Downgrade	BofA Securities	Neutral → Underperform	$10
Oct-15-21	Resumed	Cowen	Market Perform
Aug-16-21	Initiated	Stifel	Hold	$28
Aug-16-21	Initiated	Credit Suisse	Outperform	$40
Aug-16-21	Initiated	Cowen	Market Perform
Aug-16-21	Initiated	BofA Securities	Neutral	$26

Show Previous Ratings

Nov-13-25 12:02AM	Absci Corp (ABSI) Q3 2025 Earnings Call Highlights: Strategic Shifts and Strong Cash Position ... (GuruFocus.com) -22.35%
Nov-12-25 05:25PM	Absci Corporation (ABSI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Nov-11-25 07:28AM	Absci Corp (ABSI) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-10-25 08:15AM	uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
09:15AM	Loading…
Nov-06-25 09:15AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -5.77%
Oct-29-25 04:05PM	Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025 (GlobeNewswire) -6.41%
Oct-27-25 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.39%
Oct-15-25 08:00AM	Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial (GlobeNewswire) +28.21%
Oct-13-25 12:12PM	2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk (MarketBeat)
Sep-21-25 09:26AM	Absci Corporation (ABSI) Secures $64M Financing to Drive AI Drug Discovery Through 2028 (Insider Monkey)
Sep-11-25 08:00AM	Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD (GlobeNewswire) +15.13%
Aug-25-25 04:05PM	Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg (GlobeNewswire)
Aug-20-25 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-25 03:12AM	Absci Corp (ABSI) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges (GuruFocus.com) +5.05%
05:20PM	Loading…
Aug-12-25 05:20PM	Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results (GlobeNewswire)
Aug-11-25 09:31AM	Absci Corp (ABSI) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Aug-07-25 10:00AM	SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
02:00AM	Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target (GlobeNewswire)
Aug-06-25 10:00AM	Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Aug-05-25 05:15PM	Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates (Zacks)
Aug-04-25 05:15PM	Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-30-25 04:05PM	Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025 (GlobeNewswire)
Jul-25-25 09:56AM	Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains? (Zacks) -17.66%
Jul-24-25 08:45PM	Absci Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:54PM	Absci Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jul-11-25 07:15PM	Morgan Stanley Assumes Coverage on Absci Corporation (ABSI) with $7 Target (Insider Monkey)
Jul-07-25 08:30AM	iRhythm Technologies Announces Board Member Retirements and New Director Appointments (GlobeNewswire) -6.86%
08:00AM	Absci Appoints Biopharma Leader Mary Szela to Board of Directors (GlobeNewswire)
08:00AM	Loading…
May-20-25 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 08:32AM	Q1 2025 Absci Corp Earnings Call (Thomson Reuters StreetEvents)
03:17AM	Absci Corp (ABSI) Q1 2025 Earnings Call Highlights: Transition to Clinical Stage and Strong ... (GuruFocus.com)
May-13-25 05:30PM	Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results (GlobeNewswire)
04:01PM	Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease (GlobeNewswire)
May-12-25 09:35AM	What To Expect From Absci Corp (ABSI) Q1 2025 Earnings (GuruFocus.com) +6.55%
Apr-14-25 04:05PM	Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025 (GlobeNewswire)
11:40AM	Absci: FDA Announcement Provides Only A Modest Tailwind (Seeking Alpha)
Apr-03-25 03:15PM	Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous Market (Seeking Alpha) -9.88%
Mar-31-25 07:15AM	Which Healthcare Stock Is the Best Buy Right Now? (MarketBeat) -7.04%
Mar-26-25 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.54%
Mar-21-25 10:57PM	Absci Corp (ABSI) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Mar-19-25 09:08AM	Q4 2024 Absci Corp Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Absci Corp (ABSI) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... (GuruFocus.com)
Mar-18-25 04:05PM	Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire)
Mar-04-25 04:05PM	Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025 (GlobeNewswire)
04:00PM	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Absci to Participate in the KeyBanc Capital Markets Healthcare Forum (GlobeNewswire)
Mar-01-25 05:19PM	Why Absci Corporation (ABSI) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-18-25 08:00AM	Absci to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-12-25 09:24AM	Is Absci Corp. (ABSI) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
Feb-11-25 09:00AM	FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape (PR Newswire) +13.39%
Jan-24-25 11:54AM	Absci Corporation (ABSI): Pioneering AI-Driven Antibody Discovery with a Buy Rating from Needham (Insider Monkey)
Jan-22-25 01:22PM	Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside (Benzinga) +25.16%
08:00AM	Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-17-25 05:58PM	Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 (PR Newswire) +11.03%
01:54PM	Absci Corporation (ABSI): AI in Biopharma Discovery (Insider Monkey)
Jan-11-25 07:40AM	Absci, Owkin announce partnership to bring together AI platforms (TipRanks)
Jan-10-25 05:48PM	Advanced Micro Devices (AMD) Invests in Absci for AI-Driven Drug Discovery with High-Performance Computing Solutions (Insider Monkey) -11.34%
07:30AM	Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery (GlobeNewswire)
Jan-08-25 01:14PM	AMD Shares Slide as HSBC Downgrades Stock Over Nvidia Concerns; Absci Collaboration Announced (GuruFocus.com)
09:12AM	Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery (Benzinga)
07:00AM	Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery (GlobeNewswire)
06:32AM	AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips (The Wall Street Journal)
Jan-06-25 08:00AM	Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health (GlobeNewswire)
Jan-02-25 08:00AM	Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:39PM	Why Absci Corporation (ABSI) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-13-24 08:10AM	Absci highlights progress, updates across proprietary pipeline (TipRanks)
Dec-12-24 08:00AM	Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 RandD Day (GlobeNewswire) -15.98%
08:00AM	Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day (GlobeNewswire)
Nov-21-24 08:00AM	Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-20-24 09:15AM	AI's Growing Role in Transforming Healthcare Delivers Innovations in Diagnostics, Patient Care (PR Newswire)
Nov-13-24 02:07AM	Absci Corp (ABSI) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial Challenges (GuruFocus.com) -13.74%
Nov-12-24 09:23PM	Q3 2024 Absci Corp Earnings Call (Thomson Reuters StreetEvents) -14.95%
08:50AM	Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results (GlobeNewswire)
Nov-11-24 07:15AM	Absci Corp (ABSI) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com) +5.16%
Nov-07-24 08:00AM	Absci to Host R&D Day on December 12, 2024 (GlobeNewswire)
Oct-31-24 08:00AM	Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI (GlobeNewswire) -7.25%
Oct-24-24 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-15-24 08:00AM	Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024 (GlobeNewswire)
Aug-31-24 02:37PM	Absci Corporation (ABSI): A Penny Stock That Will Make You a Millionaire (Insider Monkey)
Aug-30-24 10:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Aug-21-24 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 05:30PM	Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +10.99%
04:01PM	Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results (GlobeNewswire)
Aug-12-24 08:00AM	Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI (GlobeNewswire)
Jul-31-24 04:25AM	Why Is Absci Corporation (ABSI) Among the Best Micro Cap Stocks Right Now? (Insider Monkey)
Jul-10-24 08:00AM	Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024 (GlobeNewswire)
Jul-03-24 04:00PM	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.07%
Jun-21-24 11:08AM	Is Absci Corporation (NASDAQ:ABSCI) the Best Halal Stock According to Hedge Funds? (Insider Monkey)
Jun-12-24 08:00AM	Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit (GlobeNewswire) +9.98%
May-28-24 08:00AM	Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-20-24 09:32PM	Cathie Wood Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks)
May-16-24 07:15AM	7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs (InvestorPlace)
May-15-24 03:01AM	Absci Corp (ABSI) Q1 2024 Earnings Call Transcript Highlights: Strategic Advancements and ... (GuruFocus.com)
May-14-24 11:53AM	ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:30AM	Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results (GlobeNewswire)
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pangalos Menelas N	Director	Sep 22 '25	Buy	2.66	95,785	254,788	113,960	Sep 24 04:03 PM
Bedrick Todd	SVP, CAO	Sep 22 '25	Buy	2.70	10,000	27,000	180,428	Sep 24 04:03 PM
Busch Andreas	Chief Innovation Officer	Jul 28 '25	Buy	3.04	50,000	152,000	327,264	Jul 29 08:37 AM

Black Swan Sale

50% Off Elite

FATE

Fate Therapeutics Inc

ADCT

Adc Therapeutics SA

STTK

Shattuck Labs Inc

ABSI

Absci Corp

Upgrade your FINVIZ experience